- REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- REGENXBIO to Participate in Upcoming Investor Conferences
- REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
- REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
More ▼
Key statistics
As of last trade, Regenxbio Inc (RGNX:NSQ) traded at 13.59, 14.84% above the 52 week low of 11.83 set on Feb 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.56 |
---|---|
High | 14.01 |
Low | 13.54 |
Bid | 13.55 |
Offer | 13.61 |
Previous close | 13.71 |
Average volume | 406.11k |
---|---|
Shares outstanding | 49.26m |
Free float | 45.72m |
P/E (TTM) | -- |
Market cap | 693.52m USD |
EPS (TTM) | -5.88 USD |
Data delayed at least 15 minutes, as of Jun 11 2024 16:42 BST.
More ▼